Regenxbio Inc (RGNX.OQ)
13 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2016||Independent Chairman of the Board|
|42||2009||President, Chief Executive Officer, Executive Director|
|49||2017||Chief Financial Officer|
|46||2016||Senior Vice President, General Counsel|
|55||2015||Senior Vice President - Technical Operations|
- BRIEF-Regenxbio reports third quarter financial results
- BRIEF-RTW Investments reports 5 pct passive stake in Regenxbio
- BRIEF-Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing
- BRIEF-Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD
- BRIEF-Dimension Therapeutics says co's board determined proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"